REG - OptiBiotix Health - Admission to Trading on the OTCQB Venture Market

OptiBiotix HealthAnnouncement

21/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250821:nRSU1599Wa&default-theme=true

RNS Number : 1599W  OptiBiotix Health PLC  21 August 2025

 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Admission to Trading on the OTCQB Venture Market in the United States

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes announces that its shares
("Ordinary Shares") have been approved to trade on the OTCQB Venture Market
("OTCQB") in the United States and will commence trading on the stock market
at open on Thursday 21 August 2025 under the symbol "OPTBF".

 

Trading on the OTCQB market will not impact on existing ordinary shares
admitted to trading on the AIM Market of the London Stock Exchange and no new
ordinary shares were issued through this process. The Company will continue to
make all announcements and disclosures to the London Stock Exchange through
the Regulatory News Service and is not subject to any Sarbanes-Oxley or US
Securities and Exchange Commission reporting requirements.

 

OTCQB is provided through OTC Markets Group Inc. ("OTC Markets"), located in
New York. OTC Markets operates the world's largest electronic interdealer
quotation system for US broker dealers and offers multiple media channels to
increase the visibility of OTC-listed companies. OTCQB is a well-established
market designed to provide enhanced visibility and liquidity for international
companies seeking to broaden their U.S. investor base. Independent studies
show that trading on the OTC by an international company offers a positive
effect on the liquidity of its shares.

 

Stephen O'Hara CEO, commented: "OptiBiotix is building its consumer presence
in the USA as shown by the recent launch of its appetite reducing SlimBiome¨
in Hydroxycut, the No. 1 selling weight loss supplement brand in the USA. This
follows on from launches earlier this year with new US partners such as NHT
and Daily Nouri. As we increase our brand presence in the USA the Board
believe joining the OTCQB Market will help increase our visibility to the US
investment community, broadening our shareholder base and improving
liquidity."

 

The Directors of the Company are responsible for the release of this
announcement.

 

 For further information, please contact:            www.optibiotix.com (http://www.optibiotix.com/)

 OptiBiotix Health plc
 Neil Davidson, Chairman   Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)     Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Walbrook PR Ltd                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLGDIGUDDGUG